Dr. Satish Nagula, MD

Dr. Nagula practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Nagula's NPI, 1588822993, was assigned on June 2, 2008. Dr. Nagula graduated from Yale University School of Medicine in 2003. Dr. Nagula holds New York license 239836.

Dr. Nagula's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Nagula also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Nagula's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. Dr. Nagula is also affiliated with Mount Sinai West. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Nagula to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nagula practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Nagula's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Nagula is licensed in New York.

CMS data shows 411 Medicare services from Dr. Nagula across 14 procedure codes in 2024, for 332 Medicare patients. Medicare paid $51,404 for them.

CMS counts 332 Medicare patients who saw Dr. Nagula in 2024. The largest group is 75 to 84, with 143 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 20% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nagula's median patient age at 63, with 53% women.

In 2024, Dr. Nagula wrote 140 Medicare Part D claims for 53 patients. 89% of them were for generic drugs. CMS names the drug for 93 of them, across 3 drugs with 11 or more claims each, at $3,384 in total drug cost. In 2023, CMS named 73 claims across 2 drugs.

Dr. Nagula accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nagula as offering telehealth. CMS counts 242 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Nagula, more than 93% of the clinicians it reports for that procedure.

Dmand AI links 43 papers to Dr. Nagula, published from 2011 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Stents, Pancreatic Neoplasms and Endoscopy, Gastrointestinal. Dr. Nagula has published most often in Gastrointest Endosc. Dr. Nagula's most frequent co-authors are Jonathan Michael Buscaglia, MD, Nikhil A. Kumta, MD, MS and Christopher John Dimaio, MD.

Dmand AI links Dr. Nagula to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Pancreatic Cyst and Cysts.

CMS Open Payments shows 37 general payments to Dr. Nagula from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Boston Scientific Corporation paid the most, $1,053.

Dr. Nagula graduated from Yale University School of Medicine in 2003.